The pan-Canadian Pharmaceutical Alliance’s (pCPA) Board of Directors is pleased to announce the appointment of Mauro Chies as chief executive officer (CEO), effective February 10, 2025.
November 22, 2024 - The pCPA Board of Directors is happy to announce the release of the 2023–24 impact report. This report covers an important timeframe for the pCPA, as we transitioned to a stand-alone organization and introduced a new structure with a CEO and board of directors.
November 4, 2024 - We’ve introduced a faster and easier way for manufacturers to submit price change requests for generic drugs.
July 10, 2024 - We are pleased to announce Robert Shaffer, assistant deputy minister at the Department of Health in Manitoba, has assumed the role of chair of the Board for the pCPA. Pam Barnes, director of Drug Programs and Services for the Government of Newfoundland and Labrador, is stepping into the role of vice-chair.
July 8, 2024 - The pCPA is pleased to announce that Dr. Clifford Lo will be joining the pCPA team as acting deputy CEO.
Effective May 10, 2024, Dominic Tan has assumed the responsibilities of CEO of the pCPA on an interim basis.
April 5, 2024 - Following consultations with stakeholders in the late summer and early fall of 2023, we have finalized the principles and conditions for the new pCPA Temporary Access Process (pTAP).
As of May 1, 2024, changes to the market exit process for generic drugs are in effect.
December 7, 2023 – In August 2023, the pCPA engaged with clinicians, patient groups and industry to present and hear feedback on a set of principles and conditions for a pCPA Temporary Access Process (pTAP).